Compare RAMP & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RAMP | NVCR |
|---|---|---|
| Founded | 2018 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | 1987 | 2015 |
| Metric | RAMP | NVCR |
|---|---|---|
| Price | $24.32 | $10.99 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $35.60 | $27.75 |
| AVG Volume (30 Days) | 722.8K | ★ 2.4M |
| Earning Date | 02-05-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 86614.23 | N/A |
| EPS | ★ 1.05 | N/A |
| Revenue | ★ $795,572,000.00 | $642,269,000.00 |
| Revenue This Year | $11.07 | $10.64 |
| Revenue Next Year | $9.11 | $5.37 |
| P/E Ratio | $23.26 | ★ N/A |
| Revenue Growth | 9.18 | ★ 11.17 |
| 52 Week Low | $21.71 | $9.82 |
| 52 Week High | $35.20 | $22.95 |
| Indicator | RAMP | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 39.32 | 53.89 |
| Support Level | $22.69 | $9.82 |
| Resistance Level | $25.25 | $14.97 |
| Average True Range (ATR) | 1.17 | 0.78 |
| MACD | 0.09 | 0.04 |
| Stochastic Oscillator | 39.61 | 54.56 |
LiveRamp Holdings Inc is a technology company that helps companies build enduring brand and business value by collaborating responsibly with data. A groundbreaking leader in consumer privacy, data ethics, and foundational identity, LiveRamp offers a connected customer view with clarity and context while protecting brand and consumer trust. The Company provides a data collaboration platform, essentially acting as a data collaboration hub where businesses can securely share and manage first-party consumer data with trusted partners while prioritizing data privacy and ethics.
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.